RecruitingNCT07119580

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma


Sponsor

National Taiwan University Hospital

Enrollment

90 participants

Start Date

Jul 8, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Background Intact corneal epithelium is important for the defense on the ocular surface, and the function of limbal stem cells is crucial to maintain its integrity. Certain chronic eye diseases, such as glaucoma, require long-term medication use. However, glaucoma patients often exhibit corneal punctate erosions and ocular surface inflammation. In cases where medication has been used for an extended period, patients may even show symptoms similar to limbal stem cell deficiency. Understanding how glaucoma medications affect the function of corneal limbal stem cells is a critical clinical issue. Objectives To evaluate the effect of glaucoma and anti-glaucoma agents on corneal epithelial and limbal epithelial thickness as a surrogate of limbal stem cell function, and to understand the association between tear fluid proteome and limbal function in glaucoma patients. Methods We planned to include 90 subjects with glaucoma, and analyze the absolute thickness and variation of corneal epithelium and limbal epithelium. Tear fluid samples will be collected and proteomic analysis will be performed to elucidate the association between protein. Anticipated Results To elucidate the impact of different types and cumulative doses of glaucoma medications on the thickness of the corneal epithelium and limbal epithelium, and to understand the relationship between limbal function and tear proteomics in glaucoma patients. The expected results may help develop early detection methods for changes in corneal and limbal epithelial function and provide valuable insights for future research on drug design and the protection of limbal stem cells.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how glaucoma and glaucoma medications affect the surface of the eye, particularly the limbal stem cells (which maintain the cornea) and the proteins in tear fluid. The aim is to understand whether long-term glaucoma eye drops cause damage to the eye's surface over time. **You may be eligible if...** - You are 18 or older - You are in one of three groups: healthy (no glaucoma), newly diagnosed with glaucoma or high eye pressure (on medication less than 3 months), or a long-term glaucoma patient on eye drops for over 1 year **You may NOT be eligible if...** - You have had recent eye surgery - You have significant other eye conditions that could affect the results - You are unable to tolerate eye examination procedures - You are a healthy control but have been diagnosed with glaucoma Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

National Taiwan University Hospital Hsinchu Branch

Hsinchu, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07119580


Related Trials